Why does comprehensive genomic profiling (CGP) matter for advanced patient w/breast cancer? Tune in to this episode of “Genomics in Moments” to hear more about how CGP can help patients & their healthcare teams make informed treatment decisions in #BreastCancer care.
We are proud to be a @TheScientistLLC Top Innovations award recipient in Healthcare and Diagnostics for FoundationOne®MRD! This award honors cutting-edge technology shaping the future of life science, biotechnology and healthcare.
This recognition reinforces Foundation Medicine's commitment to providing comprehensive testing solutions to transform care at each stage of the patient experience: foundationmedicine.com/press…
Hear more from our team at this year’s meeting – find time with us at Booth 1030, Hall 10. fpgo.io/r/t4RyJw
We are thrilled to announce the appointment of Chadi Nabhan, M.D., MBA, as Foundation Medicine's new chief medical officer, effective November 16, 2026.
Dr. Nabhan is an accomplished medical oncologist and hematologist with over 25 years of multi-disciplinary experience covering clinical oncology, academic research, genomics and healthcare technology.
Please join us in giving Dr. Nabhan a warm welcome! You can read the full announcement here: foundationmedicine.com/press…
Poster presentations at #ESMO26 explore methylthioadenosine phosphorylase (MTAP) loss in two genomic landscape studies in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Discuss and hear more about this research with our team – booth 1030, hall 10. Learn more: fpgo.io/r/qbf31J
With 12 pieces of research being presented, including two rapid oral presentations, our team is looking forward to joining the international oncology community at #ESMO26!
Come learn more about Foundation Medicine and how we are helping to advance precision medicine through our high-quality tests and services. Explore our accepted research: foundationmedicine.com/press…
#ESMO26 rapid oral presentations highlight insights for #ProstateCancer, exploring the clinical impact of CH HRR alterations on outcomes for PARPi use in mCRPC & evaluating the effectiveness of ctDNA tumor fraction as a prognostic biomarker for patients w/ HRR gene-mutated mCRPC.
Meet with our team at this year’s meeting, Booth 1030 in Hall 10. Learn more: foundationmedicine.com/event…
Engage and connect with the Foundation Medicine team for our series of “Booth Talks,” featuring discussions on the latest advancements in cancer care. Expert-led presentation will provide more information on the latest innovations happening in precision medicine and diagnostics.
Explore the topics below and learn more: foundationmedicine.com/event…
Join Foundation Medicine at #ESMO26! Our team looks forward to engaging with the international oncology community on the latest research advancing precision medicine and oncology care.
Visit us at Booth 1030, Hall 10 to attend expert-led discussions and hear more information about our high-quality tests and services, including our new molecular residual disease (MRD) offering.
Learn more about our programming at this year’s meeting – we hope to see you there! foundationmedicine.com/event…
Join us at @OGPREMED's Biomarkers, CDx & Precision Medicine Europe 2026 event! Connect with our team, including during a sponsored plenary session, to discuss more about biomarker development, precision medicine and the future of clinical development.
Find time with us and learn more: foundationmedicine.com/event…



















